MétaCan
Menu
Back to cohort
Record W4392652588 · doi:10.1111/apt.17936

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (<scp>PSC‐IBD</scp>): A matched analysis from the Paediatric <scp>PSC</scp> Consortium

2024· article· en· W4392652588 on OpenAlexaff
Amanda Ricciuto, Kuan Liu, Wael El‐Matary, Mansi Amin, Achiya Amir, Madeleine Aumar, Marcus Auth, Matthew D. Di Guglielmo, Eleonora Druve Tavares Fagundes, Alexandre Rodrígues Ferreira, Katryn N. Furuya, Nitika Gupta, Stephen L. Guthery, Simon Horslen, Kyle K. Jensen, Binita M. Kamath, Nanda Kerkar, Bart G.P. Koot, Trevor J. Laborda, Christine K. Lee, Kathleen M. Loomes, Cara L. Mack, Mercedes Martínez, Aldo J. Montaño‐Loza, Nadia Ovchinsky, Alexandra Papadopoulou, Emily R. Perito, Pushpa Sathya, Kathleen B. Schwarz, Uzma Shah, Eyal Shteyer, Nisreen Soufi, James P. Stevens, Amy Taylor, M. Tessier, Pamela L. Valentino, Marek Woynarowski, Mark Deneau

Bibliographic record

VenueAlimentary Pharmacology & Therapeutics · 2024
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsMemorial University of NewfoundlandUniversity of AlbertaChildren's Hospital Research Institute of ManitobaUniversity of TorontoSickKids FoundationHospital for Sick ChildrenPublic Health Ontario
FundersPSC Partners Seeking a Cure
KeywordsMedicineInflammatory bowel diseasePrimary sclerosing cholangitisGastroenterologyUlcerative colitisInternal medicineInflammatory Bowel DiseasesDisease

Abstract

fetched live from OpenAlex

BACKGROUND: Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited. AIMS: Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. METHODS: In this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE. RESULTS: 113 PSC-IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin-treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97-6.31; adjusted OR [aOR] 5.24, 95% CI 2.68-10.22). Benefit was maintained in sensitivity analyses restricted to non-transplanted patients and those with baseline moderate-severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002-7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01). CONCLUSION: Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.036
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0000.001
Open science0.0010.000
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.307
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations36
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueAlimentary Pharmacology & TherapeuticsSame topicLiver Diseases and ImmunityFrench-language works237,207